Literature DB >> 7580551

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.

M Bräutigam1, S Nolting, R E Schopf, G Weidinger.   

Abstract

OBJECTIVE: To compare the efficacy and tolerability of terbinafine and itraconazole in the treatment of toenail tinea unguium.
DESIGN: Multicentre, double blind, parallel group study.
SETTING: 17 university hospitals, one army hospital, and five dermatology practices. PATIENTS: 195 patients with clinically suspected toenail tinea and growth of dermatophytes in baseline culture; data on 86 patients in the terbinafine group and 84 patients in the itraconazole group were fully evaluated for efficacy.
INTERVENTIONS: Daily dose of 250 mg terbinafine or 200 mg itraconazole for 12 weeks, with follow up for a further 40 weeks. MAIN OUTCOME MEASURES: Mycological cure (negative results on microscopy and culture) and clinical improvement (length and area of unaffected nail) at week 52 or at discontinuation of treatment.
RESULTS: At the end of the study mycological cure rates were 81% (70 out of 86) for terbinafine and 63% (53 out of 84) for itraconazole (2P < 0.01). Negative culture was achieved in 92% (79 out of 86) in the terbinafine group and 67% (56 out of 84) in the itraconazole group (2P < 0.0001). Length of unaffected nail was 9.44 mm in the terbinafine group and 7.85 mm in the itraconazole group (2P < 0.05).
CONCLUSION: Terbinafine is more effective than itraconazole in the treatment of toenail tinea infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7580551      PMCID: PMC2550920          DOI: 10.1136/bmj.311.7010.919

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  19 in total

Review 1.  GRISEOFULVIN: BIOLOGY AND CLINICAL USEFULNESS. A REVIEW.

Authors:  D W ANDERSON
Journal:  Ann Allergy       Date:  1965-02

2.  A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize.

Authors:  N Zaias; D Drachman
Journal:  J Am Acad Dermatol       Date:  1983-12       Impact factor: 11.527

Review 3.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 4.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

5.  Treatment of onychomycosis with terbinafine.

Authors:  F Baudraz-Rosselet; T Rakosi; P B Wili; R Kenzelmann
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

6.  Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.

Authors:  M J Goodfield
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

7.  A randomized treatment duration-finding study of terbinafine in onychomycosis.

Authors:  J G van der Schroeff; P K Cirkel; M B Crijns; T J Van Dijk; F J Govaert; D A Groeneweg; D J Tazelaar; R F De Wit; J Wuite
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

8.  Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey.

Authors:  D T Roberts
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

9.  Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.

Authors:  J H Lewis; H J Zimmerman; G D Benson; K G Ishak
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

10.  Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group.

Authors:  H Hofmann; M Bräutigam; G Weidinger; H Zaun
Journal:  Arch Dermatol       Date:  1995-08
View more
  23 in total

1.  Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study.

Authors:  Geert W 't Jong; Bruno H Ch Stricker; Miriam C J M Sturkenboom
Journal:  BMJ       Date:  2004-02-26

Review 2.  Skin conditions in figure skaters, ice-hockey players and speed skaters: part II - cold-induced, infectious and inflammatory dermatoses.

Authors:  Brook E Tlougan; Anthony J Mancini; Jenny A Mandell; David E Cohen; Miguel R Sanchez
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

4.  Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits.

Authors:  M Bräutigam; G Weidinger; S Nolting
Journal:  BMJ       Date:  1998-10-17

Review 5.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 6.  Oral treatments for fungal infections of the skin of the foot.

Authors:  Sally E M Bell-Syer; Sameena M Khan; David J Torgerson
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 7.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

8.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group.

Authors:  E G Evans; B Sigurgeirsson
Journal:  BMJ       Date:  1999-04-17

9.  Treatment of toenail tinea infection. True cure seems unlikely.

Authors:  D S Buck
Journal:  BMJ       Date:  1996-02-03

Review 10.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.